Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company. The company is headquartered in Toronto, Ontario and currently employs 18 full-time employees. The company went IPO on 2015-07-13. Its long-acting IL-2 Superkine, MDNA11, is a IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Its IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials, including a Phase IIb trial for recurrent glioblastoma (GBM). Its early-stage high-affinity IL-2B biased IL-2/IL-15 Super-antagonists, from its MDNA209 platform, are being evaluated as potential therapies for autoimmune and graft-versus host diseases. Its early-stage BiSKITs (Bifunctional SuperKine ImmunoTherapies) and the T-MASK (Targeted Metalloprotease Activated SuperKine) programs are designed to enhance the ability of Superkines to treat immunologically cold tumors.
Follow-Up Questions
Medicenna Therapeutics Corp 'in CEO'su kimdir?
Dr. Fahar Merchant 2011 'den beri şirketle birlikte olan Medicenna Therapeutics Corp 'in Chairman of the Board 'ıdır.
MDNAF hissesinin fiyat performansı nasıl?
MDNAF 'in mevcut fiyatı $1.05 'dir, son işlem günde 0% decreased etti.
Medicenna Therapeutics Corp için ana iş temaları veya sektörler nelerdir?
Medicenna Therapeutics Corp Biotechnology endüstrisine ait ve sektör Health Care 'dir
Wall Street analistlerine göre, 7 analist Medicenna Therapeutics Corp için analist derecelendirmeleri gerçekleştirdi, bunlar 2 güçlü al, 5 al, 1 tut, 0 sat ve 2 güçlü sat içermektedir
